AI Article Synopsis
- Tacrolimus was approved in Japan in 2013 for treating interstitial lung disease in patients with polymyositis and dermatomyositis.
- A postmarketing surveillance study by Kuwana et al showed positive interim results after two years.
- The study found that immunosuppressive regimens containing tacrolimus were well tolerated by patients with PM/DM-associated ILD.
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.2024-0379 | DOI Listing |
Publication Analysis
Top Keywords
update tacrolimus
4
tacrolimus patients
4
patients interstitial
4
interstitial pneumonia
4
pneumonia associated
4
associated polymyositis
4
polymyositis dermatomyositis
4
dermatomyositis 3-year
4
3-year postmarketing
4
postmarketing surveillance
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!